tiprankstipranks
Trending News
More News >
InMode (INMD)
NASDAQ:INMD
Advertisement

InMode (INMD) AI Stock Analysis

Compare
2,080 Followers

Top Page

INMD

InMode

(NASDAQ:INMD)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 4o)
Rating:71Outperform
Price Target:
$16.00
▲(13.80% Upside)
InMode's overall stock score is driven by strong financial performance and attractive valuation, indicating a fundamentally sound company. However, technical analysis shows bearish momentum, and the earnings call revealed significant declines in key financial metrics, which temper the overall outlook.
Positive Factors
International Expansion
The strategic expansion into emerging markets like Argentina and Thailand positions InMode for long-term growth by tapping into new customer bases and diversifying revenue streams.
Strong Cash Position
A strong cash position provides InMode with the financial flexibility to invest in growth opportunities, weather economic downturns, and enhance shareholder value.
Consumables Revenue Growth
Growth in consumables revenue indicates strong recurring income potential, enhancing business stability and customer retention.
Negative Factors
Revenue Decline
The significant revenue decline suggests challenges in maintaining sales momentum, potentially impacting long-term growth and profitability.
Decline in Gross Margins
A decline in gross margins could indicate increased cost pressures or pricing challenges, which may affect future profitability if not addressed.
Decreased Operating Margins
The decrease in operating margins reflects potential inefficiencies or increased expenses, which could hinder the company's ability to invest in growth initiatives.

InMode (INMD) vs. SPDR S&P 500 ETF (SPY)

InMode Business Overview & Revenue Model

Company DescriptionInMode Ltd. is a global provider of innovative and minimally invasive aesthetic and medical technologies. The company specializes in devices that utilize radiofrequency (RF) technology to perform various aesthetic procedures, including body contouring, facial rejuvenation, and hair removal. InMode operates primarily in the aesthetic medicine sector, offering a range of products designed for plastic surgeons, dermatologists, and other medical professionals. Its core products include the BodyTite, FaceTite, and Morpheus8 platforms, which enhance both surgical and non-surgical treatment options for patients seeking cosmetic improvements.
How the Company Makes MoneyInMode generates revenue primarily through the sale of its medical devices and consumables used in aesthetic procedures. The company sells its devices to medical practitioners and clinics, which then use these technologies to provide services to patients. A significant portion of InMode's revenue comes from recurring sales of consumables, such as RF handpieces, that are required for ongoing treatments. Additionally, InMode benefits from partnerships with clinics and healthcare providers that offer its technologies, enhancing its market reach. The company's focus on innovation and expanding its product portfolio also contributes to its revenue growth, as new technologies attract more customers and increase usage among existing clients.

InMode Earnings Call Summary

Earnings Call Date:Nov 05, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 05, 2026
Earnings Call Sentiment Negative
The earnings call presented a mix of positive developments, such as international expansion and strong consumables growth, but these were overshadowed by significant declines in revenue, gross margins, operating margins, and net income compared to the previous year.
Q3-2025 Updates
Positive Updates
Expansion in Emerging Markets
InMode expanded its global footprint by opening a new subsidiary in Argentina and previously in Thailand, which are expected to generate initial revenue by the end of 2025.
Strong Consumables and Service Revenue Growth
Consumables and service revenues were $19.9 million, up 26% year-over-year, driven primarily by markets outside of the U.S.
Strong Financial Position
InMode ended the quarter with cash and cash equivalents, marketable securities, and deposits of $532.3 million, generating $24.5 million in cash from operating activities this quarter.
Negative Updates
Significant Revenue Decrease
Revenue for the quarter was $93.2 million, down from $130.2 million in the same period last year, largely due to the absence of $31.9 million in preorder sales.
Decline in Gross Margins
GAAP and non-GAAP gross margins in Q3 were 78%, down from 82% reported in Q3 2024, impacted by anticipated tariffs.
Decreased Operating Margins
GAAP operating margin was 22%, down from 37% in the third quarter of 2024. Non-GAAP operating margin also decreased to 25% from 40% last year.
Decline in Net Income and EPS
GAAP net income was $21.8 million, down from $50.9 million in Q3 2024. Non-GAAP net income was $24.5 million, down from $54.9 million. GAAP diluted EPS was $0.34, down from $0.65, and non-GAAP EPS was $0.38, down from $0.70.
Company Guidance
During the third quarter of 2025, InMode provided guidance that emphasized its strategic expansion and financial performance. The company reported revenues of $93.2 million, with international sales contributing $40 million, marking a 10% increase year-over-year. Consumables and service revenues saw a 26% year-over-year increase, reaching $19.9 million, driven by markets outside of the U.S. InMode maintained a strong financial position with cash and cash equivalents totaling $532.3 million as of September 30, 2025. The company reiterated its 2025 guidance, projecting revenues between $365 million and $375 million, non-GAAP gross margins between 78% and 80%, and non-GAAP earnings per diluted share between $1.55 and $1.59. The company also highlighted strategic moves, such as opening a new subsidiary in Argentina, launching a subsidiary in Thailand, and the appointment of Michael Dennison as President of North America, positioning itself for future growth despite the competitive market landscape.

InMode Financial Statement Overview

Summary
InMode demonstrates strong financial health with robust profitability, a solid balance sheet, and efficient cash flow management. The company is well-positioned in the medical devices industry, with significant revenue growth and minimal financial risk. Monitoring the slight declines in certain margins and cash flow ratios will be important to maintain this strong performance.
Income Statement
85
Very Positive
InMode's income statement reflects strong profitability with a high gross profit margin of approximately 80% and a net profit margin of 44.5% for TTM. The company has shown impressive revenue growth of 23.2% in the TTM period, indicating robust demand for its products. EBIT and EBITDA margins are also healthy, suggesting efficient operations. However, the slight decline in gross profit margin over the years could be a potential area of concern.
Balance Sheet
90
Very Positive
The balance sheet is exceptionally strong with a very low debt-to-equity ratio of 0.0097, indicating minimal leverage and financial risk. The return on equity is solid at 26.6%, showcasing effective use of equity to generate profits. The equity ratio of 88.9% further highlights the company's strong capital structure and financial stability.
Cash Flow
80
Positive
InMode's cash flow statement shows a healthy free cash flow growth rate of 25.9% in the TTM period, reflecting strong cash generation capabilities. The operating cash flow to net income ratio of 1.57 indicates efficient cash conversion. The free cash flow to net income ratio is nearly 1, suggesting that the company is effectively converting its earnings into cash. However, the slight decline in operating cash flow coverage ratio over the years warrants attention.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue494.73M394.82M492.05M454.27M357.56M206.11M
Gross Profit393.48M317.07M411.34M380.79M303.97M175.26M
EBITDA149.21M113.26M196.28M198.53M167.99M73.26M
Net Income200.57M181.28M197.92M161.52M164.97M75.03M
Balance Sheet
Total Assets734.61M785.67M863.29M644.41M478.54M295.76M
Cash, Cash Equivalents and Short-Term Investments532.31M596.47M741.61M547.38M415.91M260.53M
Total Debt5.59M7.82M9.02M4.96M4.52M1.24M
Total Liabilities81.22M81.85M75.91M89.79M62.74M40.29M
Stockholders Equity653.38M703.81M787.37M554.62M415.80M253.96M
Cash Flow
Free Cash Flow131.16M132.00M176.12M180.00M173.95M78.76M
Operating Cash Flow131.93M132.66M176.83M181.58M174.88M79.22M
Investing Cash Flow357.93M162.21M-136.06M-109.47M-160.11M-43.30M
Financing Cash Flow-326.38M-282.77M5.50M-41.09M-15.02M-12.44M

InMode Technical Analysis

Technical Analysis Sentiment
Negative
Last Price14.06
Price Trends
50DMA
14.93
Negative
100DMA
14.73
Negative
200DMA
15.43
Negative
Market Momentum
MACD
-0.31
Positive
RSI
40.33
Neutral
STOCH
23.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INMD, the sentiment is Negative. The current price of 14.06 is below the 20-day moving average (MA) of 14.51, below the 50-day MA of 14.93, and below the 200-day MA of 15.43, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INMD.

InMode Risk Analysis

InMode disclosed 61 risk factors in its most recent earnings report. InMode reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We have limited business in Russia which pose some degree of sanctions risk that cannot be entirely eliminated. Q4, 2022

InMode Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$977.99M6.5021.52%-13.98%15.94%
64
Neutral
$599.21M64.474.97%1.58%
63
Neutral
$1.24B-1.90%18.72%85.77%
55
Neutral
$1.43B-16.14-338.19%24.76%-10.41%
52
Neutral
$604.29M-5.02-24.60%4.31%3.26%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
39
Underperform
$1.15B-43.42%159.43%67.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INMD
InMode
14.06
-5.46
-27.97%
OFIX
Orthofix
15.26
-3.78
-19.85%
AXGN
AxoGen
26.87
13.40
99.48%
ESTA
Establishment Labs Holdings
68.03
22.48
49.35%
SSII
SS Innovations International
5.96
2.26
61.08%
BVS
Bioventus
7.24
-4.26
-37.04%

InMode Corporate Events

InMode Reports Q3 2025 Financial Results Amid Legal Challenges
Nov 5, 2025

On November 5, 2025, InMode Ltd. announced its financial results for the third quarter of 2025, reporting revenues of $93.2 million, a decrease from $130.2 million in the same period of 2024. The company experienced a decline in gross margins and net income compared to the previous year, attributed to lower sales in the U.S., its most profitable region. Despite the challenging economic conditions and cautious consumer sentiment, InMode remains committed to strategic investments and regional growth, highlighted by the appointment of Michael Dennison as the new President of North America. The company is also involved in ongoing legal proceedings related to a shareholder class action, with the court dismissing most of the claims but allowing for a replead.

InMode Ltd. Sees Partial Dismissal in Shareholder Class Action
Sep 18, 2025

InMode Ltd. is currently involved in a legal proceeding following a shareholder class action filed in February 2024, alleging false or misleading statements related to its business operations. On September 12, 2025, a court order dismissed 19 of the 24 statements in the complaint with leave to amend, and the company continues to deny wrongdoing and plans to defend itself vigorously.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 07, 2025